MEA Bladder Disorders Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143125
- Pages: 225
-
Format:
Short Description
The Middle East and Africa Bladder Disorders Market- By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical, and others), End User (Hospitals, Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail) Country (Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Bladder-related disorders include Cystitis - inflammation of the bladder, often from infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
The doctors perform different tests to diagnose the bladder disorder, including x-rays, urine tests, and a bladder wall examination by scope called a cystoscope. The treatment of the disorder depends on the cause of the problem, including medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first line of pharmacotherapy for Over-active Bladder (OAB) syndrome. OAB is a clinical symptom characterized by the urgency of the desire to pass urine, which is difficult to defer. Generally, the frequency of passing urine more than eight times per day is considered in OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle, reducing bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Market Segmentation:
In the Middle East and Africa, the bladder disorders market is categorized into four segments: type, treatment type, end user, and distribution channel.
On the basis of type, the Middle East and Africa bladder disorders market is segmented into Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer
On the basis of treatment type, the Middle East and Africa bladder disorders market is segmented into Surgery, Medication, Non-surgical, and others
On the basis of end-user, the Middle East and Africa bladder disorders market is segmented into Hospitals, Clinics, Ambulatory Surgery Centres, Others
On the basis of distribution channel, the Middle East and Africa bladder disorders market is segmented into direct and retail
Market Players
The major companies which are dealing in the Middle East and Africa bladder disorders market are listed below:
Medtronic
Laborie
Boston Scientific Corporation
Pfizer Inc.
Astellas Pharma Inc.
KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.)
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Axonics, Inc.
Merck & Co., Inc.
Viatris Inc.
Gaylord Chemical Company, L.L.C.
Coloplast Corp, AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Urovant Sciences, among others.
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET 24
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 TYPE LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 43
4.2 PORTER'S FIVE FORCES 44
4.3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, PIPELINE ANALYSIS 45
5 MIDDLE EAST & AFRICA BLADDER DISORDER MARKET: REGULATIONS 46
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION 46
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS 46
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS 47
6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET OVERVIEW 49
6.1 DRIVERS 51
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 51
6.1.2 GROWING GERIATRIC POPULATION 51
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS 52
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES 52
6.2 RESTRAINTS 53
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT 53
6.2.2 PRODUCTS RECALLS FROM MARKET 53
6.3 OPPORTUNITIES 53
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS 53
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS 54
6.4 CHALLENGES 55
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS 55
6.4.2 PATENT EXPIRY OF DRUGS 55
7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TYPE 57
7.1 OVERVIEW 58
7.2 OVERACTIVE BLADDER 61
7.3 URINARY INCONTINENCE 61
7.4 CYSTITIS 62
7.5 INTERSTITIAL CYSTITIS 63
7.6 BLADDER CANCER 64
7.7 OTHERS 65
8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE 66
8.1 OVERVIEW 67
8.2 MEDICATION 70
8.2.1 TOLTERODINE 71
8.2.2 MIRABEGRON 71
8.2.3 FESOTERODINE 71
8.2.4 OXYBUTYNIN 71
8.2.5 SOLIFENACIN 71
8.2.6 DARIFENACIN 71
8.2.7 TROSPIUM 71
8.2.8 OTHERS 72
8.3 SURGERY 72
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY 73
8.3.2 BLADDER REMOVAL 73
8.3.3 OTHERS 73
8.4 OTHERS 73
9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL 75
9.1 OVERVIEW 76
9.2 DIRECT 79
9.3 RETAIL 79
10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY END USER 81
10.1 OVERVIEW 82
10.2 HOSPITALS 85
10.3 CLINICS 86
10.4 AMBULATORY SURGICAL CENTERS 86
10.5 OTHERS 87
11 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY GEOGRAPHY 89
11.1 MIDDLE EAST AND AFRICA 90
11.1.1 SAUDI ARABIA 97
11.1.2 SOUTH AFRICA 99
11.1.3 UAE 101
11.1.4 EGYPT 103
11.1.5 ISRAEL 105
11.1.6 REST OF MIDDLE EAST AND AFRICA 107
12 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY LANDSCAPE 108
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 108
13 SWOT ANALYSIS 109
14 COMPANY PROFILE 110
14.1 MERCK AND CO. INC. (2021) 110
14.1.1 COMPANY SNAPSHOT 110
14.1.2 REVENUE ANALYSIS 110
14.1.3 COMPANY SHARE ANALYSIS 111
14.1.4 PRODUCT PORTFOLIO 111
14.1.5 RECENT DEVELOPMENT 111
14.2 ASTELLAS PHARMA INC. (2021) 112
14.2.1 COMPANY SNAPSHOT 112
14.2.2 REVENUE ANALYSIS 112
14.2.3 COMPANY SHARE ANALYSIS 113
14.2.4 PRODUCT PORTFOLIO 113
14.2.5 RECENT DEVELOPMENTS 113
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021) 115
14.3.1 COMPANY SNAPSHOT 115
14.3.2 REVENUE ANALYSIS 115
14.3.3 COMPANY SHARE ANALYSIS 116
14.3.4 PRODUCT PORTFOLIO 116
14.3.5 RECENT DEVELOPMENT 116
14.4 BOSTON SCIENTIFIC CORPORATION (2021) 117
14.4.1 COMPANY SNAPSHOT 117
14.4.2 REVENUE ANALYSIS 117
14.4.3 COMPANY SHARE ANALYSIS 118
14.4.4 PRODUCT PORTFOLIO 118
14.4.5 RECENT DEVELOPMENT 118
14.5 VIATRIS INC. (2021) 119
14.5.1 COMPANY SNAPSHOT 119
14.5.2 REVENUE ANALYSIS 119
14.5.3 COMPANY SHARE ANALYSIS 120
14.5.4 PRODUCT PORTFOLIO 120
14.5.5 RECENT DEVELOPMENT 120
14.6 ABBVIE (2021) 121
14.6.1 COMPANY SNAPSHOT 121
14.6.2 REVENUE ANALYSIS 121
14.6.3 PRODUCT PORTFOLIO 122
14.6.4 RECENT DEVELOPMENT 122
14.7 AXONICS, INC. (2021) 123
14.7.1 COMPANY SNAPSHOT 123
14.7.2 REVENUE ANALYSIS 123
14.7.3 PRODUCT PORTFOLIO 123
14.7.4 RECENT DEVELOPMENT 124
14.8 BLUE WIND MEDICAL (2021) 125
14.8.1 COMPANY SNAPSHOT 125
14.8.2 PRODUCT PORTFOLIO 125
14.8.3 RECENT DEVELOPMENT 125
14.9 COLOPLAST CORP. (2021) 126
14.9.1 COMPANY SNAPSHOT 126
14.9.2 REVENUE ANALYSIS 126
14.9.3 PRODUCT PORTFOLIO 127
14.10 GAYLORD CHEMICAL COMPANY, LLC (2021) 128
14.10.1 COMPANY SNAPSHOT 128
14.10.2 PRODUCT PORTFOLIO 128
14.10.3 RECENT DEVELOPMENT 128
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021) 129
14.11.1 COMPANY SNAPSHOT 129
14.11.2 REVENUE ANALYSIS 129
14.11.3 PRODUCT PORTFOLIO 130
14.11.4 RECENT DEVELOPMENT 130
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021) 131
14.12.1 COMPANY SNAPSHOT 131
14.12.2 PRODUCT PORTFOLIO 131
14.12.3 RECENT DEVELOPMENTS 132
14.13 LABORIE (2021) 133
14.13.1 COMPANY SNAPSHOT 133
14.13.2 PRODUCT PORTFOLIO 133
14.13.3 RECENT DEVELOPMENT 134
14.14 MEDTRONIC (2021) 135
14.14.1 COMPANY SNAPSHOT 135
14.14.2 REVENUE ANALYSIS 135
14.14.3 PRODUCT PORTFOLIO 136
14.14.4 RECENT DEVELOPMENTS 136
14.15 PFIZER INC. (2021) 137
14.15.1 COMPANY SNAPSHOT 137
14.15.2 REVENUE ANALYSIS 137
14.15.3 PRODUCT PORTFOLIO 138
14.15.4 RECENT DEVELOPMENTS 138
14.16 VALENCIA TECHNOLOGIES (2021) 139
14.16.1 COMPANY SNAPSHOT 139
14.16.2 PRODUCT PORTFOLIO 139
14.16.3 RECENT DEVELOPMENT 140
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021) 141
14.17.1 COMPANY SNAPSHOT 141
14.17.2 REVENUE ANALYSIS 141
14.17.3 PRODUCT PORTFOLIO 142
14.17.4 RECENT DEVELOPMENT 142
14.18 SWATI SPENTOSE (2021) 143
14.18.1 COMPANY SNAPSHOT 143
14.18.2 PRODUCT PORTFOLIO 143
14.18.3 RECENT DEVELOPMENT 143
14.19 UROVANT SCIENCES (2021) 144
14.19.1 COMPANY SNAPSHOT 144
14.19.2 PRODUCT PORTFOLIO 144
14.19.3 RECENT DEVELOPMENT 144
14.20 ZYDUS GROUP (2021) 145
14.20.1 COMPANY SNAPSHOT 145
14.20.2 PRODUCT PORTFOLIO 145
14.20.3 RECENT DEVELOPMENT 145
15 QUESTIONNAIRE 146
16 RELATED REPORTS 149
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
